N4 Pharma PLC N4 Pharma Launches New Interactive Investor Hub

TIDMN4P

N4 Pharma PLC

30 November 2023

Reach - Non-Regulatory

N4 Pharma plc

("N4 Pharma" or the "Company")

N4 Pharma Launches New Interactive Investor Hub

Company to provide shareholders with a more proactive way of communication and enquiry support

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders, the new Investor Hub brings all N4 Pharma content into a single integrated platform to better inform and engage with investors and stakeholders, including:

   --     regulatory announcements 
   --     annual and interim reports 
   --     corporate presentations 
   --     company information 
   --     interviews with the Company's directors 
   --     corporate research on N4 Pharma 

Investor Hub also provides an interactive online experience allowing Company's stakeholders to comment on and ask the N4 Pharma team questions via a portal which will be monitored.

To sign up for the N4 Pharma Investor Hub:

   1.    Visit investors.n4pharma.com . 
   2.    Follow the prompts to sign up for an investor hub account. 
   3.    Complete your account profile. 

N4 Pharma's CEO and Founder, Nigel Theobald commented :

"At N4 Pharma, we have always encouraged our shareholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our shareholders, and potential shareholders to interact with N4 Pharma. Investor Hub will give us a platform to collate all our video material, information and insights about our activities and plans in one place . We encourage our stakeholders to trial Investor Hub and to provide feedback."

For more information please contact:

 
 N4 Pharma plc                                        Via IFC Advisory 
  Nigel Theobald, CEO 
  Luke Cairns, Executive Director 
 SP Angel Corporate Finance LLP                       Tel: [phone] 
  Nominated Adviser and Joint Broker                   0470 
  Matthew Johnson/Kasia Brzozowska (Corporate 
  Finance) 
  Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate 
  Broking) 
                                                     ---------------------------------- 
 Turner Pope Investments (TPI) Limited                Tel: [phone] 
  Joint Broker                                         0050 
  Andy Thacker 
  James Pope 
                                                     ---------------------------------- 
 IFC Advisory Ltd                                     Tel: [phone] 
  Financial PR                                         6630 
  Graham Herring 
  Zach Cohen 
                                                     ---------------------------------- 
 InvestorHub                                          Sign up at investors.n4pharma.com 
  Engage with us directly at N4 Pharma Investor 
  Hub 
                                                     ---------------------------------- 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec(R) as the delivery vehicle for these antigens. As these products progress through pre--clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABLBATMTITBIJ

(END) Dow Jones Newswires

November 30, 2023 04:00 ET (09:00 GMT)